Please select the option that best describes you:

Would you offer Durvalumab as consolidation therapy to a patient with stage III NSCLC but had local recurrence treated with definitive SBRT?  

Prior to the PACIFIC trial, patients were treated with definitive chemo/rads. With local recurrence <1yr after chemorads and definitive treatment for local recurrence with SBRT, would it be reasonable to start Durvalumab?



Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more